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Summary 25 
Currently there is no standard HIV-1 DNA quantification assay for use in clinical trials and a 26 
comparison of HIV-1 assays has not been performed. Here, we evaluate two HIV-1 DNA 27 
quantification assays for their ability to accurately quantify HIV-1 DNA load in patient samples. 28 
Additionally, we have compared a number of commonly used HIV-1 latency cell for their use 29 
as HIV-1 quantification standards. We have shown that the two assays perform comparably 30 
and correlate strongly, however, one assay performs significantly better and this assay was 31 
chosen for improvement. We have also shown that J-Lat are the most suitable HIV-1 32 
quantification standard owing to the stability of the integrated viral genome. We have 33 
redesigned primers based on analyses of the HIV-1 database to update and improve the HIV-34 
1 quantification assay. 35 
 36 
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ABSTRACT   HIV-1 infection cannot be cured due to the presence of the latent reservoir (LR). 49 
Novel cure or treatment strategies, such as “shock and kill” or therapeutic vaccination, aim to 50 
reduce or eradicate the LR. Cure strategies utilise robust DNA quantification assays to 51 
measure the change in the LR in low copy scenarios. No standard assay exists, which impedes 52 
the reliable comparison of results from different therapy and vaccine trials and HIV-1 total 53 
DNA quantification methods have not been previously compared. The HIV-1 LTR (long 54 
terminal repeat) has been shown to be the best target for DNA quantification. We have 55 
analysed two HIV-1 quantification assays, both able to differentiate between the variant HIV-56 
1 DNA forms via the use of pre-amplification and primers targeting LTR. We identify a strong 57 
correlation (r=0.9759, P<0.0001) between assays and which is conserved in low copy samples 58 
(r=0.8220, P<0.0001) indicating that these assays may be used interchangeably. The RvS assay 59 
performed significantly (P=0.0021) better than the CV assay when quantifying HIV-1 total DNA 60 
in patient CD4+ T lymphocytes. Sequence analysis demonstrated that viral diversity can limit 61 
DNA quantification, however in silico analysis of the primers indicated that within the target 62 
region nucleotide miss-matches appear infrequently. Further in silico analysis using up to-63 
date sequence information led to the improvement of primers and enabled us to establish a 64 
more broadly specific assay with significantly higher HIV-1 DNA quantification capacity in 65 
patient samples (p=0.0116, n=17). 66 
 67 
Key Words: HIV-1 DNA quantification, latent reservoir, HIV-1 cure, HIV-1 therapeutic 68 
vaccines 69 
Abbreviations: RvS, Rene van der Sluis assay; CV, Claire Vandergeeten assay; CRx, Christine 70 
Rouzioux  71 
 72 
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1. Introduction 73 
The development of active antiretroviral therapy (ART) has been a major breakthrough 74 
in the treatment of human immunodeficiency virus type 1 (HIV-1) infection, effectively 75 
preventing the progression to acquired immunodeficiency syndrome (AIDS) (Brechtl et al., 76 
2001). Despite this, ART cannot completely eradicate the virus due to the presence of a 77 
replication competent latent reservoir (LR) in different cell populations including long-lived 78 
resting CD4+ T cells that harbour pro-viral DNA integrated into the genome (Chun et al., 79 
1997a; Finzi et al., 1997). Such infected cells can produce replication competent HIV-1, 80 
supporting rapid viral rebound following ART interruption (Davey et al., 1999; Joos et al., 81 
2008; Rothenberger et al., 2015). Research is therefore focused on the development of novel 82 
approaches to reduce or eliminate the LR, with the aim of developing a functional cure for 83 
HIV-1 infection.  84 
Therapeutic vaccination, administered during ART mediated virus suppression aims to 85 
stimulate the production of broad and effective immune responses, inducing sustained 86 
immune control of HIV-1 in the absence of therapy. A number of studies have explored the 87 
therapeutic potential of vaccination in both simian immunodeficiency virus (SIV) models (De 88 
Rose et al., 2008; Fuller et al., 2012; Fuller et al., 2006; Hel et al., 2002; Hel et al., 2000; Lu et 89 
al., 2003) and in human trials (Barouch et al., 2013; Garcia et al., 2013; Lévy et al., 2014; Lu et 90 
al., 2004) with vaccine agents including DNA based vaccines expressing antigen, viral vectors 91 
expressing antigen, passive transfer immunotherapy, dendritic cells (DC) primed for HIV-1 92 
antigen presentation or combinations of these (Mylvaganam, Silvestri, and Amara, 2015). 93 
Generally, these studies have demonstrated that therapeutic vaccination can achieve 94 
reduced viral loads, increased time to viral rebound, reduction in size of the LR and in inducing 95 
stronger and more sustained immune response against HIV-1 (Mylvaganam et al., 2015). 96 
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Alternatively, strategies which aim to completely eradicate the HIV-1 LR are popular in current 97 
research and clinical trials (Kim, Anderson, and Lewin, 2018). These “shock and kill” 98 
approaches utilise latency reversing agents (LRA) to induce activation of latently infected cells 99 
in the presence of ART, rendering those cells susceptible to cytolysis or immune clearance 100 
whilst limiting the chance of subsequent rounds of infection (Archin et al., 2017; Archin et al., 101 
2012; Elliott et al., 2015; Margolis et al., 2016). Adding to this, recent approaches have 102 
explored the potential of a “lock in and apoptosis” strategy that when combined with the 103 
LRAs, utilises a novel compound to antagonise the viral gag protein and prevent virus budding 104 
whilst still inducing virus apoptosis (Tateishi et al., 2017).  105 
Research focused on the reduction or elimination of the LR must utilise robust assays 106 
that can reliably and reproducibly measure the effect that the treatment or vaccine strategy 107 
has on the size of the LR. The quantification of HIV-1 DNA from peripheral blood mononuclear 108 
cells (PBMC) of patients via polymerase chain reaction (PCR) provides a useful tool to monitor 109 
the size of the viral reservoir, and a number of assays have been developed targeting different 110 
regions of the HIV-1 genome including gag, pol and the long terminal repeat (LTR) (Beloukas 111 
et al., 2009; Kabamba-Mukadi et al., 2005; Rouzioux and Avettand-Fenoël, 2018; van der Sluis 112 
et al., 2013; Vandergeeten et al., 2014; Yun, Fredriksson, and Sonnerborg, 2002). The strength 113 
of these assays is the rapid turn-around from sample collection to DNA quantification and the 114 
possibility to identify different HIV-1 DNA forms, such as integrated DNA, unintegrated linear 115 
DNA forms and 2-LTR circular DNA (De Spiegelaere et al., 2014; van der Sluis et al., 2013; 116 
Vandergeeten et al., 2014). These different HIV-1 DNA forms have been used as markers of 117 
HIV-1 persistence in a number of different studies, reviewed here (Ruggiero et al., 2017). 2-118 
LTR circular DNA is a product of abortive integration, and while some studies have suggested 119 
they are stable in CD4+ cells (Pace, Graf, and O'Doherty, 2013), they are considered markers 120 
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of recent infection and ongoing replication notwithstanding therapy (Chun et al., 1997b; 121 
Koelsch et al., 2008; Zhu et al., 2011). Only assays targeting the viral LTR allow for the 122 
discrimination of different HIV-1 forms in addition to the fact that the LTR contains some of 123 
the most conserved regions of the viral genome (van der Sluis et al., 2013). We have 124 
comprehensively analysed two HIV-1 DNA quantification assays, herein referred to as 125 
Vandergeetan, (CV) (Vandergeeten et al., 2014) and van der Sluis (RvS) (van der Sluis et al., 126 
2013), both of which target highly conserved regions in the long terminal repeat (LTR) region 127 
of the virus genome (van der Sluis et al., 2013; Vandergeeten et al., 2014) (Fig. 1). Both assays 128 
utilise a PCR pre-amplification step with primers designed to only amplify DNA which has been 129 
fully reverse transcribed, excluding the short abortive transcripts. Additionally, both assays 130 
are able to distinguish between total HIV-1 DNA and 2-LTR circular DNA with the use of 131 
alternative primer sets in the pre-amplification step. The CV assay is also able to distinguish 132 
integrated HIV-1 DNA via the use of primers targeting human Alu sequences, randomly 133 
dispersed in the human genome (Ruggiero et al., 2017; Vandergeeten et al., 2014). A 134 
prominent HIV-1 LTR based DNA assay, herein referred to as Rouzioux (CRx), was excluded 135 
from this comparison because this assay does not distinguish between different DNA types 136 
(Rouzioux, Melard, and Avettand-Fenoel, 2014). Furthermore, we have evaluated several 137 
calibration cell-lines, aiming to establish a stable and reproducible source of HIV-1 DNA for 138 
use as a standard curve. Additionally, we have analysed the primer sequences and used this 139 
information to establish an assay with broader specificity and increased sensitivity. 140 
 141 
 142 
 143 
2. Materials and Methods 144 
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2.1. Cell Lines and Calibration Standards. HIV-1 quantification standards were produced from 145 
cell lines including 8E5 (CFAR 95), ACH-2 (CFAR 349) and J-Lat 10.6 (CFAR 9849), obtained 146 
from the NIH AIDS reagent program. Additionally, we utilised SupT1-14 a previously 147 
characterised cell lined containing 14 HIV-1 copies per cell in comparing the assays (van der 148 
Sluis et al., 2013). Standards for the quantification of cell input were produced from dilutions 149 
of DNA derived from HEK293T cells (ATCC CRL-3216). ACH-2, 8E5 and J-Lat 10.6 were 150 
maintained in RPMI-1640 medium (Fisher, 11875093) supplemented with 10% heat 151 
inactivated FBS (Sigma, non-US origin, F7524) and 1% pen-strep (Fisher, 15140122) at 37 °C 152 
with 5% CO2. HEK293T cells were maintained under the same conditions with advanced 153 
DMEM (Fisher, 12491015) used for culturing. Cells were passaged to a maximum of 10 cycles 154 
prior to DNA extraction using QIAamp DNA Blood Mini Kit, according to the manufacturer’s 155 
instructions (Qiagen, 51104). DNA concentration and purity was assessed by Nanodrop 156 
analysis (Thermo Scientific, ND-200). The total number of cells and HIV-1 copy numbers were 157 
quantified using the CD3 and LTR quantification assays, respectively, and as previously 158 
described (van der Sluis et al., 2013; Vandergeeten et al., 2014). Standards were produced via 159 
a dilution series over a range of 5 logs. HIV-1 DNA standards were spiked with uninfected 160 
human genomic DNA to equalise DNA input in lower copy numbers.  161 
 162 
2.2. Study Population Clinical Sample Preparation. The present study was approved by the 163 
Institutional Review Board of the Centre Hospitalier Universitaire Vaudois and all subjects 164 
provided written informed consent. CD4+ cells were isolated from PBMCs by negative 165 
selection using paramagnetic beads (StemCell Technologies) according to supplier’s protocol. 166 
Purified CD4+ cells were digested via incubation with 0.1 mg/ml recombinant proteinase K 167 
(Roche, RPROTK-RO) in 10 nM Tris (pH 8.3) for 2 h at 56 °C. Lysate was centrifuged and 168 
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supernatant recovered and used as input in the HIV-1 quantification assays. Proteinase K 169 
lysates were stored at -80 °C until use. 170 
 171 
2.3. HIV-1 DNA Quantification Assays. Total HIV-1 DNA was quantified using both CV 172 
(Vandergeeten et al., 2014) and RvS (van der Sluis et al., 2013) LTR based HIV-1 DNA as well 173 
as CD3 cell quantification assays. Primers and probes used in HIV-1 and CD3 DNA 174 
quantification are as described previously (van der Sluis et al., 2013; Vandergeeten et al., 175 
2014).  Additionally, a commercial cell quantification kit targeting the β-actin gene was used 176 
(ABI Applied Biosystems TaqMan β-actin Detection Reagent, 401846). Pre-amplifications 177 
were performed in 25 µl reactions using Taq polymerase (Invitrogen, 10342020), as previously 178 
described (van der Sluis et al., 2013; Vandergeeten et al., 2014). Quantifications were 179 
performed in 20 µl reactions using Supermix-UDG (Invitrogen, 11730025) with the Qiagen 180 
Rotor Gene RotorQ, as described previously (van der Sluis et al., 2013; Vandergeeten et al., 181 
2014). β-actin quantifications were performed according to the manufacturer’s instructions. 182 
Reagent mixes for the quantification and pre-amplification PCR steps were adapted to the 183 
volumes used in this study, though the final concentrations remained the same as previously 184 
described (van der Sluis et al., 2013; Vandergeeten et al., 2014). 185 
 186 
2.4. Sanger DNA Sequencing. To sequence the primer and probe binding regions of both 187 
assays primers were designed in house to amplify the LTR region of patient samples (Table 1). 188 
Nested PCR was performed under the following conditions: 2 min (95 °C) followed by 35 cycles 189 
of 30 s (95 °C), 30 s (55 °C) and 1 min (72 ◦C) with a final elongation of 10 min (75 °C). The 190 
product of PCR 1 was diluted 1/10 in molecular grade water and this dilution was 191 
9 
 
subsequently used as input for PCR 2. Amplification was analysed using gel electrophoresis 192 
and further purified using a Qiagen PCR Purification Kit (28104) prior to sequencing (GATC 193 
Biotech and Source Bioscience). Patient sequences were then aligned to primer and probe 194 
sequences using BioEdit software to identify mismatches. Following this, new primers were 195 
selected to exactly match the patient sample LTR region and used to quantify the total HIV-1 196 
DNA using both assays, as described above (Table 1).   197 
 198 
3. Results 199 
3.1. Validation of assay quantification standards. Our aim was to examine the performance 200 
of the two assays CV and RvS and using the vast amount of sequence information available to 201 
date develop a new assay that will perform most optimally with the highest specificity and 202 
sensitivity. The incentive for this consideration was that both HIV-1 DNA quantification assays 203 
target the LTR of the HIV-1 genome, well established as the most conserved region of the 204 
genome, and furthermore both utilise a pre-amplification step allowing for the separate 205 
quantification of different viral life-cycle stages. In order to do so we initially aimed to define 206 
the cell quantification standard using a human genomic DNA input based on 293T cells.  We 207 
quantified the cell number using two methods; a commercial assay with primers targeting the 208 
human β-actin gene and a previously described assay targeting the human CD3 gene 209 
(Vandergeeten et al., 2014). We tested a 5 log standard range (105 to 101 cell equivalents) 210 
using both assays and found that they were within the optimum range of amplification 211 
efficiency (90-110%) and that there was no significant difference between either over 3 runs 212 
(P=0.8538) (Fig. 2A and 2B). Based on this result we selected the CD3 quantification assay 213 
because it includes a pre-amplification step consistent with the HIV-1 DNA assays. 214 
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Further, we ran the two HIV-1 quantifications assays, RvS (van der Sluis et al., 2013) and 215 
CV (Vandergeeten et al., 2014), using 5-log serial dilutions (105 to 101 HIV-1 copies per input) 216 
of the J-Lat 10.6, 8E5, SupT-14 and ACH2 cell lines. We found no significant difference 217 
between qPCR efficiency of both assays over 6 runs (P=0.0552). We next compared the HIV-218 
1 DNA content in these cell lines, aiming to determine the most appropriate cell line for use 219 
as a quantification standard. 220 
 221 
3.2 Evaluation of calibration cell lines. We evaluated HIV-1 integration model cell lines 222 
including ACH2, 8E5 and J-Lat as well as in ‘in house’ cell line, SupT-14, for their use as 223 
calibration standards. Cell lines were grown to 10 passages and the total HIV-1 per 106 cells 224 
was quantified following DNA extraction. Consistent with recent publications, we showed that 225 
HIV-1 copies per cell decreased in 8E5 cells from 1 to 0.2 copies (Fig. 3). Additionally, HIV-1 226 
copies in ACH2 cells were found to increase from 1 to 4 copies per cell. On the contrary, HIV-227 
1 DNA content was stable in both J-Lat 10.6 and SupT1-14, which contain 1 copy per cell 228 
consistent with recent studies (Sunshine et al., 2016) and 14 copies per cell as demonstrated 229 
previously (van der Sluis et al., 2013), respectively (Fig. 3). Based on these findings we used 230 
the J-Lat 10.6 to quantify patient samples in this study. 231 
 232 
3.3 HIV-1 quantification in patient samples. We then compared the two HIV-1 DNA 233 
quantification assays using patient samples. Overall, a strong correlation was found between 234 
the results produced with the RvS and CV assays (r=0.9759, P<0.0001) (Fig. 4C). Nonetheless, 235 
the mean quantification of patient samples was significantly higher when using the RvS (3.385 236 
Log10 HIV-1 copies/106 cells) HIV-1 assay compared to the CV assay (3.203 Log10 HIV-1 237 
copies/106) (P=0.0021) suggesting a slight advantage of RvS over CV when testing patient 238 
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material (Fig. 4B). A possible explanation would that the CV amplified product is longer than 239 
the RvS thus affecting the amplification efficiency. Furthermore, the implementation of 240 
software (http://unafold.rna.albany.edu) revealing folded structures indicated that more 241 
complex folded structures of the CV amplicon could also account for a lower amplification 242 
efficiency. (Fig. 5)   Of note, in 4/38 (10.52 %) of patients we observed a significant differences 243 
in quantification between the two assays (114: P=0.00101, 72: P>0.0001, 23: P>0.0001, 111: 244 
P=0.0003) (Fig. 4A). 245 
We next aimed to test the performance of the two assays when HIV-1 copy input was 246 
diluted down to 10 copies. We found that in low copies, correlation was skewed towards the 247 
CV assay (r=0.8220, P<0.0001) and that in 9/25 (36%) of samples quantification was 248 
significantly different between the assays (Fig. 4D and 4F). However, there was no significant 249 
difference between the mean quantification of low copy patient samples (P=0.1456) (Fig. 4E). 250 
 251 
3.4 HIV-1 quantification using patient tailored primers. We showed that both assays perform 252 
comparably; however, there is some discrepancy in quantification observed with some 253 
patient samples. We aimed to elucidate the cause of this discrepancy by sequencing the LTR 254 
of patient samples. Two forward and reverse primers were selected for nested LTR 255 
amplification based on identity with sequences of the Los Alamos database (Table 1). The LTR 256 
of patient samples was subsequently sequenced with the Sanger platform. Patient sequences 257 
were analysed using BioEdit and sequences were manually aligned to primer and probes used 258 
in both assays (data not shown). Based on this alignment, we selected primers tailored to 259 
patient samples (Table 1). Patient samples were quantified simultaneously with the universal 260 
and the patient tailored primers. The HIV-1 DNA copy numbers were significantly increased 261 
(131.9% and 141.6% average increase for RvS and CV assays, respectively) when matching 262 
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primers were used (Fig. 6A and 6B) with the corresponding patient samples demonstrating 263 
that sequence diversity can occasionally impair the accuracy of the assay.  264 
We subsequently interrogated the sequence information available ‘to date’ at the Los 265 
Alamos HIV-1 database. Our in silico analysis revealed that the oligonucleotide with the higher 266 
propensity for mismatches was the RvS forward pre-amplification primer, at the 5’ end (Fig. 267 
7E), when compared to the other assay primers (Fig. 7A-D). We therefore redesigned this 268 
primer in two different versions (RvS-PreF-A and RvS-PreF-B, Table 1) (Fig. 7F), to compensate 269 
the sequence diversity and circumvent 5’ end mismatches that would be the most 270 
deleterious. These two primer versions were used at equal ratio for the pre-amplification 271 
step. Our results indicate that the new primers yield a significantly higher quantification than 272 
the existing primer, and this represents and improvement on the assay (P=0.0116) (Fig. 8). 273 
Though this difference is small, our analysis suggests this primer combination will reduce the 274 
risk of mismatching in the 5’ end of the primer and increase the overall coverage and accuracy 275 
of the assay.  As it stands the in silico analysis showed that the overall primer diversity ranged 276 
between 0.04% and 0.07% as estimated using the neighbour-joining method and the Kimura-277 
2-parameter model (data not shown) suggesting that the RvS primer combination will rarely 278 
underestimate the total DNA load.  279 
 280 
 281 
 282 
4. Discussion 283 
Clinical trials assessing the efficacy of therapeutic vaccination or HIV-1 eradication 284 
strategies must utilise robust and reproducible HIV-1 DNA quantification assays. The lack of a 285 
standard quantification assay to measure total HIV-1 DNA has led to the development of a 286 
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number of ‘in-house’ assays targeting different genomic regions for quantification, but this 287 
variation may render the results of different clinical trials incomparable. We selected two HIV-288 
1 quantification assays, CV (Vandergeeten et al., 2014) and RvS (van der Sluis et al., 2013), for 289 
comprehensive evaluation to determine if results obtained were comparable and the assays 290 
could therefore be used interchangeably. These assays were selected for the ability to 291 
distinguish different HIV-1 DNA forms, including 2-LTR circular DNA, which can serve as a 292 
marker of recent infection and therefore be used to determine the success of treatment. The 293 
differential quantification of different DNA markers is facilitated by the use of a pre-294 
amplification step and primers targeting the conserved regions of the LTR of the viral genome.  295 
Recent data has suggested that 8E5, a commonly used latency model containing one 296 
copy of HIV-1 per cell, is unstable and rapidly loses HIV-1 copies during passaging (Busby et 297 
al., 2017; Wilburn et al., 2016). Further, a study has shown eveidence of ongoing replication 298 
within ACH2 cells during passaging, resulting in an increase in HIV-1 copies per cell (Sunshine 299 
et al., 2016). This study has proposed the use of J-Lat cells as quantification standards as these 300 
contain a non-replication competent copy of HIV-1 that remains stable after a number of 301 
passages (Sunshine et al., 2016). Consistent with these findings, we have compared a number 302 
of well characterised calibration cell lines and discovered that 8E5 and ACH2 cells are 303 
unsuitable for use due to the change in HIV-1 DNA copies during passaging (Busby et al., 2017; 304 
Wilburn et al., 2016). Further, we have demonstrated that J-Lat cells contain ~1 copy per cell 305 
and would therefore be the most suitable for used in DNA quantification studies. The 306 
universal use of only one cell line as a calibration standard would reduce variability of 307 
different HIV-1 DNA assays and across different labs, rendering data obtained from studies 308 
and clinical trials more comparable. Further, we demonstrate that both LTR based assays 309 
amplify well-characterised HIV-1 calibration cell lines with equal efficiency, removing the 310 
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potential of bias in quantification of patient samples arising from a bias in the amplification 311 
of the standard curve. 312 
Our data indicate that both assays perform comparably when quantifying total HIV-1 313 
DNA in patient samples as well as cell lines and that these quantifications correlate strongly. 314 
Despite this, we have shown that the RvS assay quantifies the patient set as a whole, 0.2 315 
Log10 HIV-1 copies higher than the CV assay, suggesting that the quantification of patient 316 
samples is more efficient when using this assay. When these samples were diluted to ~10 317 
copies per input the strength of the correlation of the assays was lost. This is due to inherently 318 
higher variation in the quantification of low copy samples, owing to the stochastic distribution 319 
of template within the sample. However, the assay was improved when primers were 320 
redesigned using sequences derived from a recent HIV-1 database. 321 
The RvS assay utilises primers strategically placed to bind DNA only present following 322 
first and second strand transfer of the reverse transcription process, ensuring that only fully 323 
reverse transcribed DNA is amplified and therefore increasing the specificity and accuracy of 324 
the assay (Figure 1) (van der Sluis et al., 2013). Based on this property we decided to improve 325 
the assay using an analysis of sequences from the HIV-1 database. The high degree of HIV-1 326 
sequence heterogeneity means that sequence variation will be encountered even within the 327 
most conserved regions of the genome. Our analysis showed that the forward pre-328 
amplification primer was most divergent from published sequences and we therefore 329 
redesigned this primer and suggest that two primers (Table 1) should be used to improve the 330 
accuracy and sensitivity of this assay.  331 
HIV-1 DNA quantification is an essential tool for monitoring HIV-1 vaccine and therapy 332 
trials due to its low cost, fast turnaround time and high throughput capacity. Notwithstanding 333 
its advantages, DNA based assays cannot distinguish between replication competent and 334 
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replication defective pro-virus, and will therefore overestimate the size of the replication 335 
competent LR (Rouzioux and Avettand-Fenoël, 2018; Ruggiero et al., 2017). Despite this, 336 
recent studies have suggested defective pro-virus contributes to HIV-1 pathogenesis, and so 337 
measuring the size of all pro-virus present in a sample is useful marker of vaccine or treatment 338 
success and projection for disease progression (Rouzioux and Avettand-Fenoël, 2018; 339 
Ruggiero et al., 2017). In any case these described assays are a cheaper, faster and more 340 
practical alternative to the cell based viral outgrowth assay (VOA) which is able to specifically 341 
quantify only replication competent pro-virus by measuring virus production in PBMCs 342 
following activation (Rouzioux and Avettand-Fenoël, 2018). Here we demonstrate that two 343 
HIV-1 quantification assays perform comparably and can therefore be used interchangeably 344 
in clinical settings. Furthermore, we have improved the RvS assay through increasing the 345 
coverage of the diverse HIV-1 populations that can be detected with the assay. 346 
 347 
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Fig. 1. HIV-1 LTR region: Locations of primers and probes for the CV, RvS and CRx assays. The 507 
numbers indicate the position on the HXB2 genome. For CV assay forward quantification 508 
primer anneals to Lambda T heel sequence on the forward pre-amplification primer.  509 
 510 
Fig. 1. Comparison of standards and assay performance: A) 5 log serial dilution of human 511 
genomic DNA quantified using CD3 and β-actin qPCR. B) Average amplification efficiency of 512 
CD3 and β-actin assays (n=3). C) 5 log serial dilution of J-Lat clone 10.6 cells using CV and RvS. 513 
D) Average amplification efficiency of CV and RvS assays. 514 
 515 
Fig. 3. Quantification using different cell lines: Quantification of three cell lines containing 1 516 
HIV-1 copy per cell (8E5, J-Lat) and 14 HIV-1 copies per cell (SupT1-14). A five log dilution 517 
series for each cell line was performed and used as input for the assay. Quantification of each 518 
dilution was pooled and standardised to determine the average HIV-1 copies per cell.  519 
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 520 
Fig. 4. Quantification of patient samples: A) Pellets of PBMCs or CD4+ cells extracted using 521 
proteinase K digestion or Qiagen DNA extraction. Total HIV-1 was quantified using RvS and CV 522 
assays and cells were quantified using the CD3 assay. Statistical significance determined using 523 
the multiple t-test, Holm-Sidak method, with alpha = 5.000%. B, E) Dot plot showing 524 
differences in mean quantification for undiluted and low copy quantification. Significance 525 
determined by paired t-test. D) Samples were diluted to 10 copies per reaction and quantified 526 
using both assays. Statistical significance determined using the multiple T test, Holm-Sidak 527 
method, with alpha = 5.000%. C, F) Correlation of all samples and correlation of diluted, low 528 
copy samples, respectively. Solid red line represents linear regression and green dashed line 529 
represents perfect correlation. 530 
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 531 
Fig. 5. The probable secondary structure of single stranded HIV-1 DNA produced using the 532 
The mfold Web Server (http://unafold.rna.albany.edu): A) Depicts the 152 nt CV amplicon 533 
(HxB2: 522→643) and B) Depicts the 122 nt RvS amplicon (HxB2: 452→603).     534 
 535 
Fig. 6. Quantification with sequence matched primers: Primers designed to match sequences 536 
were compared with assay primers: A) Comparison of CV primers to sequence matched 537 
25 
 
primers. B) Comparison of RvS primers to sequence matched primers. Statistical significance 538 
determined using the multiple t-test, Holm-Sidak method, with alpha = 5.000%. 539 
 540 
Fig. 7. Analysis of primer and probe sequence identity to published HIV-1 sequences: A) RvS 541 
probe sequence B) RvS pre-amplification reverse primer C) RvS qPCR reverse primer D) Region 542 
targeted by both VC Probe and RvS qPCR forward primer E) RvS pre-amplification forward 543 
primer F) Modified assay primer encompassing both primer A and B, where one has a 544 
nucleotide removed (Table 1) n = the number of sequences analysed per oligonucleotide. 545 
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 546 
Fig. 8. Comparison of new compared to existing primers to quantify patient samples. Samples 547 
were quantified with an equal mix of primer A and B (Table 1) to increase coverage of the 548 
genome.  Significance determined by paired t-test. 549 
 550 
 551 
 552 
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TABLE 1 Primers used for the amplification of patient sample LTRs and primers matched to 553 
patient sequences. For tailored and redesigned primers nucleotide positions that vary from 554 
the universal assay primer are underlined. 555 
 556 
 557 
 558 
Name Stage Function  Sequence Position on HXB2 
Seqout-F Sequencing PCR 1 Forward CACACACAAGGCTACTTCCCTGATTAGCAGAACT 57-90 
Seqout-R Sequencing PCR1 Reverse CTTAATACTGACGCTCTCGCACCCATCTCTCT 815-784 
Seqin-F Sequencing PCR2 Forward GGGACTTTCCGCTGGGGACTTTCC 350-373 
Seqin-R Sequencing PCR2 Reverse TCTCTCTCCTTCTAGCCTCCGCTAGTCA 790-763 
RvS-preF_132 Pre-amplification Forward CAACCTTCAGAAGCTGCATAWAAGCAGCYGCT 409-440 
RvS -preR_132 Pre-amplification Reverse AGCAAGCCGAGTCCTCGCGTC 688-707 
RvS -preF_108 Pre-amplification Forward GAGCCCGTGGATGCTGCATAWAAGCAGCYGCT 409-440 
RvS -preR_108 Pre-amplification Reverse AGCACAGCCGAGTCCTGCGTC 688-707 
RvS –qF_ 124 qPCR Forward GGGCGCCACTGCTAGAGAA 625-643 
CV-preF_124 Pre-amplification Forward ATGCCACGTAAGCGAAACTCTGGGTCTCTCTDGCTGGAC 452-471 
CV -preR_124 Pre-amplification Reverse CCATCTCTCTCCCTTCTAGC 775-793 
CV -preF_132 Pre-amplification Forward ATGCCACGTAAGCGAAACTCTGGGTCTCTCTDGCTAGAC 452-471 
CV –preF_108 Pre-amplification Forward ATGCCACGTAAGCGAAACTCTGGGTCTCTCTDGTCAGA 452-471 
RvS-preF-A Pre-amplification Forward ARCCCTCAGAHGCTGCATAWAAGCAGCYGCT 410-440 
RvS-preF-B Pre-amplification Forward ARCCCTCAGAHGCTGCATAWAAGCAGCYGC 410-439 
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 561 
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